Risks and benefits of preoperative high dose methylprednisolone in surgical patients: a systematic review

Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy: a randomized double-blind placebo-controlled trial

OBJECTIVE

To determine the effects of preoperative dexamethasone on surgical outcome after laparoscopic cholecystectomy (LC).

SUMMARY BACKGROUND DATA

Pain and fatigue are dominating symptoms after LC and may prolong convalescence.

METHODS

In a double-blind, placebo-controlled study, 88 patients were randomized to intravenous dexamethasone (8 mg) or placebo 90 minutes before LC. Patients received a similar standardized anesthetic, surgical, and multimodal analgesic treatment. All patients were recommended 2 days postoperative duration of convalescence. The primary endpoints were fatigue and pain. Preoperatively and at several times during the first 24 postoperative hours, we measured C-reactive protein (CRP) and pulmonary function, pain scores, nausea, and number of vomiting episodes were registered. Analgesic and antiemetic requirements were recorded. Also, on a daily basis, patients reported scores of fatigue and pain before and during the first postoperative week and the dates for resumption of work and recreational activities.

RESULTS

Eight patients were excluded from the study, leaving 40 patients in each study group for analysis. There were no apparent side effects of the study drug. Dexamethasone significantly reduced postoperative levels of CRP (P = 0.01), fatigue (P = 0.01), overall pain, and incisional pain during the first 24 postoperative hours (P < 0.05) and total requirements of opioids (P < 0.05). In addition, cumulated overall and visceral pain scores during the first postoperative week were significantly reduced (P < 0.05). Dexamethasone also reduced nausea and vomiting on the day of operation (P < 0.05). Resumption of recreational activities was significantly faster in the dexamethasone group versus placebo group (median 1 day versus 2 days) (P < 0.05).

CONCLUSION

Preoperative dexamethasone (8 mg) reduced pain, fatigue, nausea and vomiting, and duration of convalescence in patients undergoing noncomplicated LC, when compared with placebo, and is recommended for routine use.

[Frequency of postoperative fever in children with congenital heart disease undergoing cardiovascular surgery and associated risk factors]

OBJECTIVES

To determine the frequency of postoperative fever in children with congenital heart disease who undergo cardiovascular surgery, and the risk factors associated.

PATIENTS AND METHODS

In a prospective cohort study, 100 children under the age of less than 9 years were followed-up during hospitalization in order to detect fever after cardiac surgery. Preoperative, perioperative, and postoperative variables were assessed to determine their relationship with postoperative fever. The cases were patients who developed fever. Multivariate analysis was used, and the odds ratio (OR) and 95% confidence intervals (95% CI) were calculated.

RESULTS

The frequency of postoperative fever was 46%. Fever appeared within 24 hours of surgery in 56% cases. In 32/46 (70%) cases, fever remitted within 72 hours. Fever was more common in patients who underwent open-heart surgery than in those treated with a closed technique (28 vs. 18, P = 0.045). Prolonged extracorporeal circulation (OR = 1.024; 95% CI, 1.004-1.045), aortic cross-clamping (OR = 2.83; 95% CI, 1.21-6.61) and postoperative infections (OR = 24.07; 95% CI, 7.2-75.0) were the risk factors associated with the development of postoperative fever.

CONCLUSIONS

Postoperative fever is common in children with congenital heart disease. The identification of risk factors associated to the development of fever should help clinicians to identify the cause of fever in this group of patients.

Randomized study of the benefits of preoperative corticosteroid administration on the postoperative morbidity and cytokine response in patients undergoing surgery for esophageal cancer

OBJECTIVE

To investigate whether preoperative corticosteroid administration plays a role in attenuating postoperative morbidity.

SUMMARY BACKGROUND DATA

There is as yet no consensus on the beneficial effects of steroids in alleviating surgical stress.

METHODS

A total of 66 patients undergoing surgery for thoracic esophageal cancer were randomly categorized preoperatively into two groups of 33 patients each. One group was administered an intravenous infusion of methylprednisolone (10 mg/kg body weight) 30 minutes before the surgery (MP group), while the other group received a placebo infusion (control group). The primary endpoint was organ system failure during the first 7 days after surgery. Comparisons of surgery-related complications, cytokine responses, and blood counts were also made between the two groups.

RESULTS

The percentage of patients in the MP group who had one or more organ system failures was 33%, significantly lower than the corresponding percentage of 61% in the control group. The surgery-related complication rate and long-term survival rate were similar in the two groups. The peak plasma levels of interleukin (IL)-1 receptor antagonist, IL-6, and IL-8 were significantly lower in the MP group than in the control group. Changes in the plasma levels of IL-10 were significantly larger in the MP group. No significant differences in the circulating lymphocyte and neutrophil counts were observed between the groups.

CONCLUSIONS

The results suggest that prophylactic administration of corticosteroids is associated with a decrease in postoperative morbidity in patients undergoing invasive surgery. The laboratory data suggest that corticosteroids may attenuate surgical stress-induced inflammatory responses both directly by suppressing the release of proinflammatory cytokines and via inducing IL-10 synthesis.

High-dose methylprednisolone for acute closed spinal cord injury--only a treatment option

BACKGROUND

A systematic review of the evidence pertaining to methylprednisolone infusion following acute spinal cord injury was conducted in order to address the persistent confusion about the utility of this treatment.

METHODS

A committee of neurosurgical and orthopedic spine specialists, emergency physicians and physiatrists engaged in active clinical practice conducted an electronic database search for articles about acute spinal cord injuries and steroids, from January 1, 1966 to April 2001, that was supplemented by a manual search of reference lists, requests for unpublished additional information, translations of foreign language references and study protocols from the author of a Cochrane systematic review and Pharmacia Inc. The evidence was graded and recommendations were developed by consensus.

RESULTS

One hundred and fifty-seven citations that specifically addressed spinal cord injuries and methylprednisolone were retrieved and 64 reviewed. Recommendations were based on one Cochrane systematic review, six Level I clinical studies and seven Level II clinical studies that addressed changes in neurological function and complications following methylprednisolone therapy.

CONCLUSIONS

There is insufficient evidence to support the use of high-dose methylprednisolone within eight hours following an acute closed spinal cord injury as a treatment standard or as a guideline for treatment. Methylprednisolone, prescribed as a bolus intravenous infusion of 30 mg per kilogram of body weight over fifteen minutes within eight hours of closed spinal cord injury, followed 45 minutes later by an infusion of 5.4 mg per kilogram of body weight per hour for 23 hours, is only a treatment option for which there is weak clinical evidence (Level I- to II-1). There is insufficient evidence to support extending methylprednisolone infusion beyond 23 hours if chosen as a treatment option.

Corticosteroids and anesthesia

PURPOSE OF REVIEW

For decades, anesthesiologists and surgeons have prophylactically provided 'stress steroids' to patients with presumed adrenocortical suppression. Other indications for glucocorticoids have included the suppression of cerebral or airway edema, the inhibition of systemic inflammatory responses to cardiopulmonary bypass, and the treatment of shock states possibly associated with adrenocortical insufficiency. Some recent studies have either restated or challenged the conventional supraphysiological doses of 'stress steroids', while others have investigated the efficacy of glucocorticoids in improving various aspects of postoperative recovery.

RECENT FINDINGS

In 2001, Jabbour summarized the normative rationale and dose regimen for stress-dose steroids in patients who have been receiving corticosteroids. A few months later, Brown and Buie concluded from their literature review that such patients can be safely managed with only physiologic or maintenance glucocorticoid administration. A torrent of reports on the antiemetic effects of dexamethasone generally indicate that this drug does reduce the incidence of postoperative nausea and vomiting, with somewhat delayed but prolonged efficacy, and acts synergistically with 5-HT3 receptor antagonists. Other authors have studied the administration of corticosteroids to patients undergoing major abdominal and other operations, and have found beneficial effects on various complications.

SUMMARY

While the conventional practice concerning 'stress steroids' is probably harmless and possibly beneficial, similar benefits might be seen with lower prophylactic doses. Alternatively, new uses for these old agents are arising, and may enable us to improve the convalescence of larger numbers of our patients.

Neurological and functional status 1 year after acute spinal cord injury: estimates of functional recovery in National Acute Spinal Cord Injury Study II from results modeled in National Acute Spinal Cord Injury Study III

OBJECT

In the second National Acute Spinal Cord Injury Study (NASCIS II) investigators evaluated several standard neurological parameters but not functional activity. This has led to questions concerning the clinical importance of the increase in neurological recovery observed following administration of methylprednisolone (MP) within 8 hours of acute spinal cord injury (SCI). The safety of the therapy has also been questioned.

METHODS

Both neurological and functional recovery were assessed in NASCIS III, a trial that followed an almost identical protocol to NASCIS II. In the current analysis locally weighted scatterplot smoothing (LOESS) nonparametric regression is used to model the extent of recovery in the Functional Independence Measure (FIM) that is predicted by improvement in the NASCIS/American Spinal Cord Injury Association motor scores that were documented in NASCIS III 1 year after SCI, and the models are applied to the extent of motor recovery demonstrated in NASCIS II. The models predict improvement in FIM that would be expected from the motor function recovery observed in NASCIS II. Estimates are provided overall and for patients with complete and incomplete neurological loss at time of injury. The authors review recent evidence obtained from randomized studies documenting adverse effects that may result from high-dose MP therapy. The relationship between motor function and FIM is strongly nonlinear and dependent on initial level of injury and degree of injury severity. In the best statistical model, the expanded motor score could be used to explain 77.2% of the variability in the FIM. Based on the mean MP-related 3.6-unit improvement in the motor score for patients with complete injuries and 7.3 for those with incomplete injuries owed to MP in NASCIS II, 18.6% of patients would improve six or more FIM points and 9% nine or more points, respectively. In those with complete neurological injury, the mean motor improvement of 3.6 predicted that 63.9% of the patients would improve three or more FIM points and 12.1% six or more points to a maximum of eight points. Of those with incomplete neurological injury, a 7.3 mean improvement in motor function predicted that 27.4% would gain six or more FIM points and that 21% would gain nine or more points to a maximum of 15 points. Analysis of the current best evidence from SCI and other randomized surgical trials in which high-dose MP has been administered provides no grounds for concern about commonly studied adverse effects.

CONCLUSIONS

The extent of MP therapy-related motor function recovery observed in NASCIS II predicted clinically important recovery in the FIM. Reasons to be cautious with regard to this prediction include the lack of robustness in statistical modeling, some loss of validity in the FIM, and considerable heterogeneity in the SCI population. Whatever functional activity is ascribed to high-dose MP therapy, it is does not appear to be associated with risk of adverse outcomes.

Methylprednisolone and acute spinal cord injury: an update of the randomized evidence

OBJECTIVES

Randomized trials are widely recognized as providing the most reliable evidence for assessing efficacy and safety of therapeutic interventions. This evidence base is used to evaluate the current status of methylprednisolone (MPSS) in the early treatment of acute spinal cord injury.

METHODS

Medline, CINAHL, and other specified databases were searched for MeSH headings "methylprednisolone and acute spinal cord injury." The Cochrane Library and an existing systematic review on the topic were also searched.

RESULTS

Five randomized controlled trials were identified that evaluated high-dose MPSS for acute spinal cord injury. Three trials by the NASCIS group were of high methodologic quality, and a Japanese and French trial of moderate to low, methodologic quality. Meta-analysis of the final result of three trials comparing 24-hour high-dose MPSS with placebo or no therapy indicates an average unilateral 4.1 motor function score improvement (95% confidence interval 0.6-7.6, P = 0.02) in patients treated with MPSS. This neurologic recovery is likely to be correlated with improved functional recovery in some patients. The safety of this regimen of MPSS is evident from the spinal cord injury trials and a systematic review of 51 surgical trials of high-dose MPSS.

CONCLUSION

High-dose MPSS given within 8 hours of acute spinal cord injury is a safe and modestly effective therapy that may result in important clinical recovery for some patients. Further trials are needed to identify superior pharmacologic therapies and to test drugs that may sequentially influence the postinjury cascade.